Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Liproxstatin-1
- Development stage
- Preclinical
- Modality
- Small Molecules
- Administration
- Intraperitoneal, Intrathecal, Intracerebroventricular, Stereotactic
01
Overview
Liproxstatin-1 is a ferroptosis inhibitor. It has been shown to partially alleviate anemia symptoms, increase the numbers of erythroblastic island (EBI) macrophages and EBIs, and reduce levels of reactive oxygen species (ROS) and lipid ROS in EBI macrophages in a mouse model of impaired erythropoiesis. This suggests its role in protecting EBI macrophages from ferroptosis to support erythropoiesis.
- Other names
- Liproxstatin 1Liproxstatin1Liproxstatin-1
02
Targets
VDAC1 (Hexokinase 2–voltage-dependent anion channel 1 complex)
Beyond the preview
Go deeper on Liproxstatin-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Liproxstatin-1.